Publication Topic

Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Stanton ME, Butenhoff JL, Stevenson LA. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol Sci 74:382–292.

Rogers JM, Abbott BD. 2003. Screening for developmental toxicity of tobacco smoke constituents. Toxicol Sci 75:227–228.

Rogers EH, Hunter ES, Rosen MB, Rogers JM, Lau C, Hartig PC, Francis BM, Chernoff N. 2003. Lack of evidence for intergenerational reproductive effects due to prenatal and postnatal undernutrition in the female CD-1 mouse. Reprod Toxicol 17:519–525.

Tarka-Leeds DK, Herr DW, Klinefelter GR, Rogers JM. 2003. Effects of gestational exposure to ethane dimethanesulfonate in CD-1 mice: Microtia and preliminary hearing tests. Birth Defects Res Part B, Dev Reprod Toxicol 68:383–390.

Rogers JM, Setzer RW, Branch S, Chernoff N. 2003. Chemically-induced supernumerary ribs in CD-1 mice: Size distribution and dose-response. Birth Defects Res Part B, Dev Reprod Toxicol 71:17–25.

Grasty RC, Grey BE, Lau CS, Rogers JM, 2003. Prenatal window of susceptibility to perfluorooctane sulfonate-induced neonatal mortality in the Sprague-Dawley rat. Birth Defects Res Part B, Dev Reprod Toxicol 68:465–471.

Sarangapani R, Gentry PR, Covington TR, Teeguarden JG, and Clewell HJ. 2003. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal Toxicol 15(10):987–1016.

Gentry PR, Covington TR, Clewell HJ, Andersen ME. 2003. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone. J Toxicol Environ Health A 66(23):2209–2225.

Choksi NY, Jahnke GD, St Hilaire C, Shelby MD. 2003. Role of thyroid hormones in human and laboratory animal reproductive health. Birth Defects Res. (B) Develop Reprod Toxicol 68:479–491, DOI: 10.1210/er.2015-1106.

Clewell H, Crump K, Covington T, Gentry R, Yeager J. A risk assessment for inhaled arsenic based on urinary arsenic concentration using a pharmacokinetic model. Poster presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2003.

Guo LT, Zhang X, Kuang W, Xu H, Liu LA, Vilquin J-T, et al. (2003) Laminin a2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul Disord 13:207–215.

Dressman D, Araishi K, Imamura M, Sasaoka T, Liu LA, Engvall E, Hoffman EP. 2002. Delivery of a- and b-sarcoglycan by recombinant adeno- associated virus: Efficient rescue of muscle, but differential toxicity. Hum Gene Ther 13:1631–1646.

Patel LB, Walden GL, Kaminsky MM, Bailey RE, McMillan DA. Peroxide degradation kinetics during use of Crest Whitestrips. Toxicologist 66(1-S):269, 2002.

Clewell HJ, Teeguarden J, McDonald T, Sarangapani R, Lawrence G, Covington T, Gentry R, Shipp A. 2002. Review and evaluation of the potential impact of age and gender-specific pharmacokinetic differences on tissue dosimetry. Crit Rev Toxicol 32(5):329–389.

Gentry PR, Covington TR, Andersen ME, Clewell HJ. 2002. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol 36:51–68.

Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. 2002. A novel phenylaminotetralin radioligand reveals a sub-population of histamine H1 receptors. J Pharmacol Exper Therapeut 302:328–336. DOI: 10.1124/jpet.302.1.328

Bergman RL, Inzana KD, Monroe WE, Shell LG, Liu LA, Engvall E, Shelton GD. 2002. Dystrophin-deficient muscular dystrophy in a labrador retriever. J Am Anim Hosp Assoc 38:255–261.